vocabria Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vocabria, and what generic alternatives are available?
Vocabria is a drug marketed by Viiv Hlthcare and is included in one NDA. There are two patents protecting this drug.
This drug has one hundred and twenty-five patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this compound. Additional details are available on the cabotegravir sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Vocabria
Vocabria will be eligible for patent challenges on January 21, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 28, 2026. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for vocabria?
- What are the global sales for vocabria?
- What is Average Wholesale Price for vocabria?
Summary for vocabria
| International Patents: | 125 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 20 |
| Patent Applications: | 4 |
| What excipients (inactive ingredients) are in vocabria? | vocabria excipients list |
| DailyMed Link: | vocabria at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for vocabria
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for vocabria
US Patents and Regulatory Information for vocabria
vocabria is protected by three US patents and three FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of vocabria is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting vocabria
N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a- -hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5- ,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HIV-1 IN AN ADULT IN COMBINATION WITH RILPIVIRINE
(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5- ,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG
FDA Regulatory Exclusivity protecting vocabria
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
NEW PATIENT POPULATION
Exclusivity Expiration: ⤷ Sign Up
REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 207966 ATLAS-2M
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | VOCABRIA | cabotegravir sodium | TABLET;ORAL | 212887-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Viiv Hlthcare | VOCABRIA | cabotegravir sodium | TABLET;ORAL | 212887-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Viiv Hlthcare | VOCABRIA | cabotegravir sodium | TABLET;ORAL | 212887-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Viiv Hlthcare | VOCABRIA | cabotegravir sodium | TABLET;ORAL | 212887-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Viiv Hlthcare | VOCABRIA | cabotegravir sodium | TABLET;ORAL | 212887-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for vocabria
When does loss-of-exclusivity occur for vocabria?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 06239177
Patent: Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
Estimated Expiration: ⤷ Sign Up
Patent: 06307101
Patent: Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
Estimated Expiration: ⤷ Sign Up
Austria
Patent: 16026
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0610030
Patent: composto, processo para a preparação de um composto, método de tratamento de uma infecção por hiv em um humano, uso de um composto, e, composição farmacêutica
Estimated Expiration: ⤷ Sign Up
Patent: 0617842
Patent: composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 06282
Patent: DERIVE POLYCYCLIQUE DE LA CARBAMOYLPYRIDONE A ACTIVITE INHIBITRICE SUR L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASEINHIBITORY ACTIVITY)
Estimated Expiration: ⤷ Sign Up
Patent: 26956
Patent: DERIVE DE CARBAMOYLPYRIDONE POLYCYCLIQUE AYANT UNE ACTIVITE D'INHIBITION SUR L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1212903
Patent: Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
Estimated Expiration: ⤷ Sign Up
Patent: 1346376
Patent: Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 15151
Estimated Expiration: ⤷ Sign Up
Patent: 16331
Estimated Expiration: ⤷ Sign Up
Patent: 20345
Estimated Expiration: ⤷ Sign Up
Patent: 22052
Estimated Expiration: ⤷ Sign Up
Patent: 24601
Estimated Expiration: ⤷ Sign Up
Patent: 14024
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 74117
Estimated Expiration: ⤷ Sign Up
Patent: 65580
Estimated Expiration: ⤷ Sign Up
Patent: 45206
Estimated Expiration: ⤷ Sign Up
Patent: 87225
Estimated Expiration: ⤷ Sign Up
Patent: 84520
Estimated Expiration: ⤷ Sign Up
Patent: 72281
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 4162
Patent: ПОЛИЦИКЛИЧЕСКОЕ КАРБАМОИЛПИРИДОНОВОЕ ПРОИЗВОДНОЕ, ОБЛАДАЮЩЕЕ ИНГИБИТОРНОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ИНТЕГРАЗЫ ВИЧ (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
Estimated Expiration: ⤷ Sign Up
Patent: 0702080
Patent: ПОЛИЦИКЛИЧЕСКОЕ КАРБОМОИЛПИРИДОНОВОЕ ПРОИЗВОДНОЕ, ОБЛАДАЮЩЕЕ ИНГИБИТОРНОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ИНТЕГРАЗЫ ВИЧ
Estimated Expiration: ⤷ Sign Up
Patent: 0801144
Patent: ПОЛИЦИКЛИЧЕСКОЕ КАРБАМОИЛПИРИДОНОВОЕ ПРОИЗВОДНОЕ, ОБЛАДАЮЩЕЕ ИНГИБИТОРНОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ИНТЕГРАЗЫ ВИЧ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 52434
Patent: DÉRIVÉ DE CARBAMOYLPYRIDONE BICYCLIQUE AYANT UNE ACTIVITÉ D'INHIBITION DE LA VIH INTÉGRASE (BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITING ACTIVITY)
Estimated Expiration: ⤷ Sign Up
Patent: 74117
Patent: DERIVE POLYCYCLIQUE DE LA CARBAMOYLPYRIDONE A ACTIVITE INHIBITRICE SUR L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
Estimated Expiration: ⤷ Sign Up
Patent: 50212
Patent: DÉRIVÉ DE CARBAMOYLPYRIDONE POLYCYCLIQUE AYANT UNE ACTIVITÉ D'INHIBITION SUR L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE)
Estimated Expiration: ⤷ Sign Up
Patent: 65580
Patent: Dérivés de carbamoylpyridone polycyclique dotés d'une activité inhibitrice de l'intégrase du VIH (Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity)
Estimated Expiration: ⤷ Sign Up
Patent: 27007
Patent: Dérivé de carbamoylpyridone polycyclique doté d'une activité inhibitrice de l'intégrase du VIH (Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity)
Estimated Expiration: ⤷ Sign Up
Patent: 45206
Patent: DERIVE DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTE D'UNE ACTIVITE INHIBITRICE DE L'INTEGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
Estimated Expiration: ⤷ Sign Up
Patent: 87225
Patent: DÉRIVÉ DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTÉ D'UNE ACTIVITÉ INHIBITRICE DE L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
Estimated Expiration: ⤷ Sign Up
Patent: 87226
Patent: DÉRIVÉ DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTÉ D'UNE ACTIVITÉ INHIBITRICE DE L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
Estimated Expiration: ⤷ Sign Up
Patent: 84519
Patent: DÉRIVÉS DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTÉS D'UNE ACTIVITÉ INHIBITRICE DE L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
Estimated Expiration: ⤷ Sign Up
Patent: 84520
Patent: DÉRIVÉ DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTÉ D'UNE ACTIVITÉ INHIBITRICE DE L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
Estimated Expiration: ⤷ Sign Up
Patent: 72281
Patent: DÉRIVÉ DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTÉ D'UNE ACTIVITÉ INHIBITRICE DE L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
Estimated Expiration: ⤷ Sign Up
Finland
Patent: 0210017
Estimated Expiration: ⤷ Sign Up
France
Patent: C0041
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 07227
Patent: POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY
Estimated Expiration: ⤷ Sign Up
Patent: 72282
Patent: 具有 整合酶抑制活性的多環氨基甲烷吡啶酮衍生物 (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVES HAVING HIV INTEGRASE INHIBITORY ACTIVITY HIV)
Estimated Expiration: ⤷ Sign Up
Patent: 49742
Patent: 具有HIV整合酶抑制活性的多環氨甲酰吡啶酮衍生物 (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
Estimated Expiration: ⤷ Sign Up
Patent: 51191
Patent: 具有HIV整合酶抑制活性的多環氨基甲酸吡啶酮衍生物 (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 37795
Estimated Expiration: ⤷ Sign Up
Patent: 44978
Estimated Expiration: ⤷ Sign Up
Patent: 56603
Estimated Expiration: ⤷ Sign Up
Patent: 400039
Estimated Expiration: ⤷ Sign Up
Patent: 100022
Estimated Expiration: ⤷ Sign Up
Patent: 100023
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 6555
Estimated Expiration: ⤷ Sign Up
Patent: 5206
Patent: נגזרת של קרבאמוילפירידון רב-טבעתי, הרכב רוקחי המכיל אותה והשימוש בה (Polycyclic carbamoylpyridone derivative, pharmaceutical composition comprising the same and use thereof)
Estimated Expiration: ⤷ Sign Up
Patent: 5207
Patent: נגזרת של קרבאמוילפירידון רב-טבעתי, הרכב רוקחי המכיל אותה, השימוש בה ותהליך להכנתה (Polycyclic carbamoylpyridone derivative, pharmaceutical composition comprising the same, use and process for preparation thereof)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 2006088173
Patent: ＨＩＶインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
Estimated Expiration: ⤷ Sign Up
Patent: 2007049675
Patent: ＨＩＶインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
Estimated Expiration: ⤷ Sign Up
Patent: 95353
Estimated Expiration: ⤷ Sign Up
Patent: 31689
Estimated Expiration: ⤷ Sign Up
Patent: 17257
Estimated Expiration: ⤷ Sign Up
Patent: 08540343
Estimated Expiration: ⤷ Sign Up
Patent: 09079058
Patent: POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 465580
Estimated Expiration: ⤷ Sign Up
Patent: 2021512
Estimated Expiration: ⤷ Sign Up
Patent: 45206
Estimated Expiration: ⤷ Sign Up
Patent: 84520
Estimated Expiration: ⤷ Sign Up
Patent: 72281
Estimated Expiration: ⤷ Sign Up
Luxembourg
Patent: 0210
Estimated Expiration: ⤷ Sign Up
Patent: 446
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 2718
Patent: DERIVADO DE CARBAMOILPIRIDONA POLICICLICO QUE TIENE ACTIVIDAD INHIBIDORA DE LA INTEGRASA DE HIV. (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY.)
Estimated Expiration: ⤷ Sign Up
Patent: 2216
Patent: Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
Estimated Expiration: ⤷ Sign Up
Patent: 07013351
Patent: DERIVADO DE CARBAMOILPIRIDONA POLICICLICO QUE TIENE ACTIVIDAD INHIBIDORA DE LA INTEGRASA DE HIV. (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY.)
Estimated Expiration: ⤷ Sign Up
Patent: 08005137
Patent: DERIVADO DE CARBAMOILPIRIDONA POLICICLICA QUE TIENE ACTIVIDAD INHIBIDORA EN VIH INTEGRASA. (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE.)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 460
Patent: DERIVE POLYCYCLIQUE DE LA CARBAMOYLPYRIDONE A ACTIVITE INHIBITRICE SUR L'INTEGRASE DU VIH
Estimated Expiration: ⤷ Sign Up
Patent: 879
Patent: DERIVE DE CARBAMOYLPYRIDONE POLYCYCLIQUE AYANT UNE ACTIVITE D'INHIBITION SUR L'INTEGRASE DU VIH
Estimated Expiration: ⤷ Sign Up
Netherlands
Patent: 0676
Estimated Expiration: ⤷ Sign Up
Patent: 1109
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 2339
Patent: Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 9525
Estimated Expiration: ⤷ Sign Up
Patent: 0111
Estimated Expiration: ⤷ Sign Up
Patent: 17010
Estimated Expiration: ⤷ Sign Up
Patent: 21018
Estimated Expiration: ⤷ Sign Up
Patent: 23042
Estimated Expiration: ⤷ Sign Up
Patent: 075165
Estimated Expiration: ⤷ Sign Up
Patent: 081892
Estimated Expiration: ⤷ Sign Up
Patent: 161315
Patent: Polysyklisk karbamoylpyridonderivat som har integrase inhibitorisk aktivitet
Estimated Expiration: ⤷ Sign Up
Philippines
Patent: 007502373
Patent: Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 74117
Estimated Expiration: ⤷ Sign Up
Patent: 65580
Estimated Expiration: ⤷ Sign Up
Patent: 45206
Estimated Expiration: ⤷ Sign Up
Patent: 84520
Estimated Expiration: ⤷ Sign Up
Patent: 72281
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 74117
Estimated Expiration: ⤷ Sign Up
Patent: 65580
Estimated Expiration: ⤷ Sign Up
Patent: 45206
Estimated Expiration: ⤷ Sign Up
Patent: 84520
Estimated Expiration: ⤷ Sign Up
Patent: 72281
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 74117
Estimated Expiration: ⤷ Sign Up
Patent: 65580
Estimated Expiration: ⤷ Sign Up
Patent: 45206
Estimated Expiration: ⤷ Sign Up
Patent: 87225
Estimated Expiration: ⤷ Sign Up
Patent: 84520
Estimated Expiration: ⤷ Sign Up
Patent: 72281
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0708970
Patent: Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
Estimated Expiration: ⤷ Sign Up
Patent: 0803423
Patent: Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1363875
Estimated Expiration: ⤷ Sign Up
Patent: 1504998
Estimated Expiration: ⤷ Sign Up
Patent: 1580310
Estimated Expiration: ⤷ Sign Up
Patent: 1848819
Estimated Expiration: ⤷ Sign Up
Patent: 080009733
Patent: POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY
Estimated Expiration: ⤷ Sign Up
Patent: 080064182
Patent: POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE
Estimated Expiration: ⤷ Sign Up
Patent: 130133061
Patent: POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY
Estimated Expiration: ⤷ Sign Up
Patent: 140097438
Patent: POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY
Estimated Expiration: ⤷ Sign Up
Patent: 160003889
Patent: ＨＩＶ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체 (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 37268
Estimated Expiration: ⤷ Sign Up
Patent: 46324
Estimated Expiration: ⤷ Sign Up
Patent: 67197
Estimated Expiration: ⤷ Sign Up
Patent: 69357
Estimated Expiration: ⤷ Sign Up
Patent: 67868
Estimated Expiration: ⤷ Sign Up
Patent: 43531
Estimated Expiration: ⤷ Sign Up
Patent: 92304
Estimated Expiration: ⤷ Sign Up
Patent: 06792
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 78931
Estimated Expiration: ⤷ Sign Up
Patent: 0716635
Patent: Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
Estimated Expiration: ⤷ Sign Up
Patent: 0800988
Patent: Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 568
Patent: ПОЛІЦИКЛІЧНЕ ПОХІДНЕ КАРБАМОЇЛПІРИДОНУ ЯК ІНГІБОР ВІЛ-ІНТЕГРАЗИ[ПОЛИЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ КАРБАМОИЛПИРИДОНА КАК ИНГИБИТОР ВИЧ-ИНТЕГРАЗЫ (POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE AS HIV-INTEGRASE INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Viet Nam
Patent: 404
Patent: Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering vocabria around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Norway | 340111 | ⤷ Sign Up | |
| Hungary | S2100022 | ⤷ Sign Up | |
| Taiwan | 200800988 | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | ⤷ Sign Up |
| Poland | 3045206 | ⤷ Sign Up | |
| Cyprus | 1115151 | ⤷ Sign Up | |
| Slovenia | 1874117 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for vocabria
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1874117 | 122014000066 | Germany | ⤷ Sign Up | PRODUCT NAME: DOLUTEGRAVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER SOLVAT DAVON, EINSCHLIESSLICH DOLUTEGRAVIRNATRIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140116 |
| 1874117 | 2014C/038 | Belgium | ⤷ Sign Up | PRODUCT NAME: DOULUTEGRAVIR SODIQUE; AUTHORISATION NUMBER AND DATE: EU/1/13/892 20140121 |
| 2465580 | CR 2021 00010 | Denmark | ⤷ Sign Up | PRODUCT NAME: CABOTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/20/1481 20201221 |
| 1874117 | 2023C/545 | Belgium | ⤷ Sign Up | PRODUCT NAME: DOULUTEGRAVIR SODIQUE; AUTHORISATION NUMBER AND DATE: EU/1/13/892 20140121 |
| 2465580 | CA 2021 00010 | Denmark | ⤷ Sign Up | PRODUCT NAME: CABOTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/20/1481 20201221 |
| 1874117 | 30/2014 | Austria | ⤷ Sign Up | PRODUCT NAME: DOLUTEGRAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON, EINSCHLIESSLICH DOLUTEGRAVIR-NATRIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 (MITTEILUNG) 20140121 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
